新济医药拟赴港IPO 加快推进创新制剂临床研究

Core Insights - Guangzhou New Ji Pharmaceutical Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds primarily for clinical research, capacity expansion, and commercialization of existing pipeline products [1] - The company has not achieved profitability in recent years and plans to accelerate global clinical development and regulatory approval of its core products [1][4] Company Overview - Established in 2007, New Ji Pharmaceutical is an innovation-driven pharmaceutical technology company focused on the development and commercialization of high-end formulation new drugs [3] - The company has developed two core products and three other pipeline products, leveraging its soluble microneedle formulation technology platform and nasal inhalation formulation technology platform [3] Product Development - The first core product, dexmedetomidine microneedle patch, targets preoperative sedation for pediatric and adult patients, enhancing patient comfort and clinical efficiency [3] - As of March 2025, the Phase I clinical trial for the microneedle patch has been completed, with the pediatric indication currently in Phase IIa trials expected to conclude in Q3 2026 [3][4] Financial Performance - New Ji Pharmaceutical has generated revenue primarily through contract research organization (CRO) services and drug marketing authorization holder (MAH) business, with no self-developed products on the market [6] - The company's revenues for 2023, 2024, and the first half of 2025 were approximately 54.1 million, 49.0 million, and 28.1 million respectively, with net losses of approximately 63.7 million, 147 million, and 20.8 million [6] Future Plans - The company intends to enhance its core product's global clinical trials and regulatory approvals, improve delivery capabilities, and accelerate global commercialization [4] - New Ji Pharmaceutical anticipates continued significant expenditures and losses as it expands its product pipeline and establishes a sales team for future product launches [7]